Omeros Corp.

Omeros Corp. is a clinical-stage biopharmaceutical company discovering, developing and commercializing small-molecule and protein therapeutics targeting inflammation, coagulopathies and disorders of the central nervous system. Lead drug product Omidria (OMS302) for lens replacement surgery is under review for marketing approval by both FDA and the European Medicines Agency, with U.S. commercial launch planned for H2/14. Omeros' five other clinical programs are focused on schizophrenia; Huntington's disease and cognitive impairment; addictive and compulsive disorders; complement-related diseases; and preventing problems associated with surgical procedures. Omeros' proprietary G protein-coupled receptor (GPCR) platform is making available many new GPCR drug targets and corresponding compounds to the pharmaceutical industry for drug development.

Expert Comments:

Jason Kolbert, Maxim Group (2/20/15)
"Omeros Corp. announced results from the first cohort in the phase 2 trial of OMS721, its complement inhibitor, in atypical hemolytic uremic syndrome. All three patients treated with the lowest dose planned showed meaningful improvements in measures of disease, justifying treating a second cohort with a mid-level dose of OMS721. . .we see this as a success for OMS721. . .we are raising our price target to $30/share from $28/share."

George Zavoico, MLV & Co (2/18/15)
"We are raising our one year price target for Omeros Corp. from $19/share to $38/share after a thorough analysis of the company's outlook for 2015 and beyond. We increased our previous U.S. market projections for Omidria after Omeros doubled its sales force to 40 sales representatives, and foresee several potential catalysts for Omeros in 2015. . .with its comfortable cash position, we think Omeros is in a much better position to negotiate partnerships for Omidria's ex-U.S. markets or for other assets, and is well-prepared for Omidria's imminent market launch in the U.S."

Zacks Equity Research (2/10/15)
"One company that looks well positioned for a solid gain but has been overlooked by investors lately is Omeros Corp. This medical products stock has actually seen estimates rise over the past month for the current fiscal year by about 5.3%, but that is not yet reflected in its price. . .this year's expected earnings growth over the prior year is 25.6%, which should ultimately translate into price appreciation." -Zacks Equity Research

"Omeros Corp. just received Centers for Medicare and Medicaid Services reimbursement approval for Omidria, its first FDA-approved drug. The company actually received better pricing than the Street had anticipated. . .with Omeros' product, surgeons will receive a better product from a single-source, FDA-regulated company." read more >

"Omeros Corp.'s product, Omidria (phenylephrine + ketorolac), was approved on May 30 of this year. Omidria is a simple combination of two older drugs that have been in the public domain for quite some time. One is a mydriatic or pupil-dilating agent, and the other is an anti-inflammatory and analgesic. The product was designed for use in cataract and intraocular lens replacement surgery, and it results in patients having less post-operative pain. The company will start selling Omidria on Jan. 1, 2015, and just recently, on Oct. 30, the product received pass-through reimbursement approval from the Center for Medicare & Medicaid Services. Now Omidria can be reimbursed by Medicare, Medicaid and many private insurers beyond the cost of the surgical procedure itself. Omeros' reimbursement will be based on the product's wholesale acquisition cost of $465 per single-use vial, which would cover a single procedure. . . .instead of having to use compounded products or homebrews to do lens surgery, the surgeon can now use a product that is FDA-approved, proven sterile and safe, and reimbursable by payers. Physicians should be using it as standard of care. I don't think there is an obstacle to adoption of Omidria at this point." read more >

"I think Omeros Corp. is on the cusp of an inflection point. At the end of May, the company's Omidria (phenylephrine + ketorolac) irrigation solution for intraocular lens replacement surgery was approved. . .Omidria should have a big effect on this very large market. One of the important issues for investors is that Omeros is likely to be marketing Omidria itself, which is prudent since the company can focus on centers that do a lot of these procedures. It won't need a huge sales force. . .the benefit is that Omeros collects all the revenue, and doesn't have to share the profit. . .recently Omeros got a very favorable decision from the Centers for Medicare and Medicaid Services (CMS) on reimbursement. The company requested, and received, pass-through reimbursement status, effective Jan. 1, 2015, which means that Omidria's cost will not be bundled with the reimbursement for an intraocular replacement surgery procedure. Omeros is guiding to a launch early next year, just as the pass-through status becomes effective. . .we'll be watching the quarterly sales revenue numbers to better gauge market penetration. . .we see a pretty healthy revenue stream coming from Omidria. . ." read more >

More Comments

Experts Commenting on This Company

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.